Abstracts tagged "fibromyalgia"

Abstract Number: 44 • 2016 ACR/ARHP Annual Meeting
Ambroxol for Fibromyalgia. One-Group Pretest-Posttest Open Label Clinical Observation
Laura-Aline Martinez-Martinez¹, Luis-Fernando Perez², Gumaro Acosta², Lizbeth Becerril³, Pedro Rodriguez-Henriquez⁴, Omar-Eloy Muñoz-Monroy⁵, Luis H. Silveira⁶, Angelica Vargas Guerrero⁷ and Manuel Martínez-Lavín⁷, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, TX, Mexico, ²National Institute of Cardiology, Mexico, Mexico, ³Hospital Juarez, Mexico, Mexico, ⁴Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁵Hospital Militar, Mexico City, Mexico, ⁶Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ⁷Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
Background/Purpose: A consistent line of investigation proposes that fibromyalgia is a sympathetically maintained neuropathic pain syndrome. Moreover it has been suggested that dorsal root ganglia…
Abstract Number: 2217 • 2016 ACR/ARHP Annual Meeting
Adherence to Drug Therapy in Patients with Fibromyalgia
Guillermo Bennasar Sr.¹, Anastasia Secco² and Marta Mamani³, ¹Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ²Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ³Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina
Background/Purpose: As in other chronic diseases, adherence to the treatment regimen of patients with fibromyalgia (FM) is low (between 30 and 80%), depending on the…
Abstract Number: 48 • 2016 ACR/ARHP Annual Meeting
Fibromyalgia Impact Is a Potential Mediator for the Associations of Self-Efficacy and Pain Catastrophizing with Physical Functioning in Persons with Fibromyalgia
Sun Yu¹, Lori Lyn Price², Jeffrey B. Driban¹, William F. Harvey¹ and Chenchen Wang¹, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA
Background/Purpose: Fibromyalgia (FM) is a chronic multidimensional disorder that causes physical and psychological impairment, incurring significant healthcare costs. Self-efficacy and pain catastrophizing have been shown…
Abstract Number: 2221 • 2016 ACR/ARHP Annual Meeting
Recognition of Secondary Fibromyalgia Using an Index of 3 Components of the Multi-Dimensional Health Assessment Questionnaire: 90% Agreement with ACR Criteria for Fibromyalgia
Kathryn Gibson^1,2, Isabel Castrejón³, Theodore Pincus³ and Katherine J. Bryant⁴, ¹Liverpool Hospital, Sydney, Sydney, Australia, ²Ingham Research Institute, Liverpool, Australia, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴University of New South Wales, Sydney, Australia
Background/Purpose: Secondary fibromyalgia (FM) is seen 15-20% of patients with rheumatoid arthritis (RA) (1), systemic lupus erythematosus (SLE) (2), osteoarthritis (OA), and other rheumatic diseases.…
Abstract Number: 119 • 2015 ACR/ARHP Annual Meeting
Triage in Chronic Rheumatic Diseases: Quantitative Physician Estimates for Inflammation (Reversible), Damage (Irreversible), and Distress in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia Seen in Usual Care
Isabel Castrejón¹, Kathryn A. Gibson², Ruchi Jain¹, Annie Huang¹, Joel A. Block³ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Liverpool, Australia, ³Rush University Medical Center, Chicago, IL
Background/Purpose: A physician estimate of a patient’s global status (DOCGL) often is most often the most efficient of all 7 rheumatoid arthritis (RA) core data…
Abstract Number: 2307 • 2015 ACR/ARHP Annual Meeting
Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)
Harvey Moldofsky¹, R Michael Gendreau², Daniel J. Clauw³, Judith Gendreau⁴, Benjamin Vaughn⁵, Bruce Daugherty⁴, Amy Forst⁶, Gregory Sullivan⁷ and Seth Lederman⁸, ¹Ctr for Sleep & Chronobiology, Centre for Sleep/Chronobiology, Toronto, ON, Canada, ²Gendreau Consulting LLC, Poway, CA, ³Anesthesiology, University of Michigan, Ann Arbor, MI, ⁴Tonix Pharmaceuticals, New York, NY, ⁵Statistics, Rho, Chapel Hill, NC, ⁶Clinical Development, Tonix Pharmaceuticals, San Jose, CA, ⁷Clinical Development, Tonix Pharmaceuticals, NEW YORK, NY, ⁸Research and Development, Tonix Pharmaceuticals, Inc., New York, NY
Background/Purpose: The importance of nonrestorative sleep in the pathophysiology of fibromyalgia (FM) suggests that treatments that improve sleep quality would address global symptoms. TNX-102 SL1a…
Abstract Number: 154 • 2015 ACR/ARHP Annual Meeting
Clinical Features of Fibromyalgia in Patients with Rheumatoid Arthritis Predict Lower Power Doppler Scores on Ultrasound
Aneela Mian¹, Khaldoun Chaabo², Julekha Wajed³, Bruce W. Kirkham⁴ and Toby Garrood⁵, ¹Academic Rheumatology, King's College London, London, United Kingdom, ²Rheumatology, Guy's and St Thomas NHS Trust, London, United Kingdom, ³Rheumatology, Guys' and St Thomas' NHS Trust, London, United Kingdom, ⁴Rheumatology, Guy's and St. Thomas' Foundation Hospital NHS Trust, London, United Kingdom, ⁵Rheumatology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: Up to 20% of patients with RA have coexisting fibromyalgia(FM). This can make treatment decisions challenging in clinical practice as disease activity scores can…
Abstract Number: 2308 • 2015 ACR/ARHP Annual Meeting
Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)
R Michael Gendreau¹, Daniel J. Clauw², Judith Gendreau³, Bruce Daugherty³ and Seth Lederman⁴, ¹Gendreau Consulting LLC, Poway, CA, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Tonix Pharmaceuticals, New York, NY, ⁴Research and Development, Tonix Pharmaceuticals, Inc., New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by symptoms that include widespread pain and sleep disruption. Clinical studies that rely on patient self-reported outcome measures such as pain…
Abstract Number: 1090 • 2015 ACR/ARHP Annual Meeting
Characteristics and Trajectories of Child Pain, Function, and Psychological Outcomes Associated with Conversion Disorder in Intensive Interdisciplinary Pediatric Pain Rehabilitation
Cara Hoffart¹ and Dustin Wallace², ¹Rheumatology and Integrative Pain Management, Children's Mercy Hospital, Kansas City, MO, ²Integrative Pain Management and Developmental and Behavioral, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Given the degree of compromise in quality of life, there is a critical need to identify the natural history of pain and disability in…
Abstract Number: 2309 • 2015 ACR/ARHP Annual Meeting
Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study
Seth Lederman¹, R Michael Gendreau², Daniel J. Clauw³, Lesley M. Arnold⁴, Judith Gendreau⁵, Bruce Daugherty⁵ and Amy Forst⁶, ¹Research and Development, Tonix Pharmaceuticals, Inc., New York, NY, ²Gendreau Consulting LLC, Poway, CA, ³Anesthesiology, University of Michigan, Ann Arbor, MI, ⁴Psychiatry, University of Cincinnati, Cincinnati, OH, ⁵Tonix Pharmaceuticals, New York, NY, ⁶Clinical Development, Tonix Pharmaceuticals, San Jose, CA
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and sleep disturbance. Treatments that improve sleep quality in FM patients may improve fibromyalgia by a…
Abstract Number: 1091 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Multidisciplinary Pain Rehabilitation Programs for Patients with Fibromyalgia Syndrome: A Systematic Review
Niall Halliday^1,2, Caroline Treanor², Rose Galvin³ and Jason Brooks⁴, ¹Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, Northern Ireland, ²Physiotherapy, Beaumont Hospital, Dublin, Ireland, ³Clinical Therapies, University of Limerick, Limerick, Ireland, ⁴Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, Ireland
Background/Purpose: Fibromyalgia syndrome (FMS) is a common, chronic pain condition with complex multiple symptoms. Combinations of therapies in a multidisciplinary pain rehabilitation program (MPRP) are…
Abstract Number: 2310 • 2015 ACR/ARHP Annual Meeting
Evaluation of Fibromyalgia Syndrome in Patients Undergoing Peritoneal Dialysis
Taskin Senturk¹, Gokhan Sargin² and Hakan Akdam³, ¹Rheumatology, Adnan Menderes University School of Medicine, Aydin, Turkey, ²Rheumatology, Adnan Menderes University Rheumatology, Aydin, Turkey, ³Nephrology, Adnan Menderes University, Nephrology, Aydin, Turkey
Background/Purpose: Fibromyalgia syndrome (FMS) is characterized by widespread pain, fatigue, memory problems. The syndrome is present in about %2-8 of general population. However, knowledge about this…
Abstract Number: 1427 • 2015 ACR/ARHP Annual Meeting
Analgesic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Experimental Animal Models of Fibromyalgia
Yuki Domon¹, Naohisa Arakawa¹, Shun-ichi Yasuda², Kensuke Saeki², Mayumi Kano², Masami Kato² and Yutaka Kitano¹, ¹Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan, ²Hashima Laboratory, Nihon Bioresearch Inc., Gifu, Japan
Background/Purpose: Mirogabalin (DS-5565) is a novel ligand of the α2δ subunit of voltage-gated calcium channels. Mirogabalin possesses unique binding characteristics to α2δ subunits, and potent…
Abstract Number: 2311 • 2015 ACR/ARHP Annual Meeting
Safety of Pregabalin for Treatment of Fibromyalgia Is Comparable Between Subjects with Moderate or Severe Baseline Widespread Pain
Andrew Clair¹ and Birol Emir², ¹Pfizer Inc, New York, NY, ²Primary Care Business Unit, Pfizer Global Research and Development, New York, NY
Background/Purpose: Pregabalin has demonstrated efficacy and safety for the treatment of pain associated with fibromyalgia (FM) and is approved by the US Food and Drug…
Abstract Number: 1443 • 2015 ACR/ARHP Annual Meeting
A Multiple Ascending-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirogabalin in Healthy Elderly Subjects
Karen Brown¹, Yoshihiro Kumagae¹, Shoichi Ohwada², Vance Warren¹, Hamim Zahir¹ and Victor Dishy¹, ¹Daiichi Sankyo Pharma Development, Edison, NJ, ²Daiichi Sankyo Co., Ltd., Tokyo, Japan
Background/Purpose: Mirogabalin (DS-5565) is a preferentially selective a2d-1 ligand intended for treatment of pain associated with fibromyalgia and neuropathic pain. We evaluated the safety, tolerability,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].